Related Experiment Videos
Mega dose intravenous methylprednisolone in bilateral simultaneous optic neuritis
A Panagariya1, R K Sureka, R Singh
1Department of Neurology, SMS Medical College and Hospital, Jaipur.
The Journal of the Association of Physicians of India
|April 25, 2000
Summary
Megadose intravenous methylprednisolone effectively treated bilateral simultaneous optic neuropathy (BSON) of unknown cause. This treatment significantly improved visual acuity and visual evoked potentials (VEP) in all patients.
Area of Science:
- Neurology
- Ophthalmology
Background:
- Bilateral simultaneous optic neuropathy (BSON) presents a diagnostic challenge.
- Etiologies of BSON require thorough investigation, including advanced imaging and cerebrospinal fluid analysis.
Purpose of the Study:
- To evaluate the efficacy of high-dose intravenous methylprednisolone for BSON of unknown origin.
- To assess treatment outcomes in patients with BSON.
Main Methods:
- A cohort of 15 neurology patients with BSON underwent investigations to rule out known causes.
- Patients received a single course of intravenous methylprednisolone (1 gm/day adults, 500 mg/day children) for three days.
- Visual acuity and visual evoked potentials (VEP) were measured before and after treatment.
Main Results:
- The study population had a female predominance with a mean age of 28 years.
- All patients demonstrated improvement in visual acuity.
- Statistically significant improvements in P100 latencies of VEP were observed (P < 0.001).
Conclusions:
- Intravenous methylprednisolone is a recommended treatment for BSON.
- This route of administration is preferred over oral or retrobulbar steroid therapies for BSON.